Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...

For patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment options include a long-acting beta-agonist (LABA) alone or a LABA combined with an inhaled corticosteroid ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

Please provide your email address to receive an email when new articles are posted on . The risk for major malformations was similar for pregnant women with asthma treated with long-acting ...

Due to lack of power, the results did not allow for a conclusion to be drawn. Overall, moderate-quality evidence indicated that tiotropium + LABA/ICS vs. tiotropium + placebo decreased hospital ...

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...

A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

Respiratory Drugs Long-acting muscarinic antagonists (LAMA) have been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and are now being considered for patients with ...

The four studies supported the decision to remove the Boxed WARNING for the ICS/LABA class. The labels of medicines that contain both an ICS and LABA retain a Warning and Precaution related to the ...